Mushrooms recognised as edible have been collected and cultivated for many years. In the Nordic countries, the interest for eating mushrooms has increased. In order to ensure that Nordic consumers will be supplied with safe and well characterised, edible mushrooms on the market, this publication aims at providing tools for the in-house control of actors producing and trading mushroom products. The report is divided into two volumes: a. Volume I: “Mushrooms traded as food - Nordic questionnaire and guidance list for edible mushrooms suitable for commercial marketing b. Volume II: Background information, with general information in section 1 and in section 2, risk assessments of more than 100 mushroom species All mushrooms on the lists have been risk assessed regarding their safe use as food, in particular focusing on their potential content of bioactive constituents.
The book provides valuable information on wild plants and their ethnopharmacological properties, discussion on ethnobotany, phytotherapy, diversity, chemical and pharmacological properties including antifungal, anti-inflammatory and antiprotozal properties. The chapters include a wide range of case studies, giving updated evidence on importance of wild plant resources from different countries including Nepal, India, Brazil, Chile, Argentina, Colombia, Egypt, Peru, etc. In addition, some specific species are used to explain their potential properties. Discussing traditional usage and pharmacological properties of wild plants, this book is entirely different from other related publications and useful for the researchers working in the areas of conservation biology, botany, ethnobiology, ethnopharmacology, policy making, etc.
Chaetomium genus was established by Gustav Kunze in 1817. According to Index Fungorum Partnership, there are 273 Chaetomium species accepted till now. Members of the genus Chaetomium are capable of colonizing various substrates and are well-known for their ability to degrade cellulose and to produce a variety of bioactive metabolites. More than 200 compounds have been reported from this genus. A huge number of new and bioactive secondary metabolites associated with unique and diverse structural types, such as chaetoglobosins, epipolythiodioxopiperazines, azaphilones, depsidones, xanthones, anthraquinones, chromones, and steroids, have been isolated and identified. Many of the compounds have been reported to possess significant biological activities, such as antitumor, antimalarial, cytotoxic, enzyme inhibitory, antimicrobial, phytotoxic, antirheumatoid and other activities. Chaetomium taxa are frequently reported to be cellulase and ligninase producers with the ability to degrade cellulosic and woody materials. This is the first, comprehensive volume covering Chaetomium genus in detail. It includes the latest research, methods, and applications, and was written by scholars working directly in the field. The book also contains informative illustrations and is fully referenced for further reading.
In the last few decades, DNA-based tools for the investigation of fungal taxonomy, signal transduction and regulation, differentiation processes and biosynthetic potential have accelerated advances in our understanding of the Mycota. This completely updated and revised second edition presents a selection of exciting issues involving basic and applied aspects of fungal physiology and genetics. In 14 chapters, respected experts provide an overview of traditional, topical and future aspects of basic fungal principles and potential applications in biotechnology. The contributions will bring scientists up-to-date on the latest developments, and help students familiarize themselves with the different topics.
Structure and Chemistry (Part E)
A review of the literature.
Using recent examples and important case studies, The Fundamentals of Early Clinical Drug Development: From Synthesis Design to Formulation demonstrates the central role℗¡that organic synthesis plays in the early clinical evaluation of potential drug candidates.